

527 Rec'd PCT/PTO 07 DEC 2000
09/719017

Atty. Docket #: PH-98/032

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INTERNATIONAL APPL. NO.: PCT/FR99/01343 :
INTERNATIONAL FILING DATE: June 8, 1999 :
APPLICANT: Jerome Pierrard et al :
SERIAL NO: : ART UNIT:
FILED: Herewith : EXAMINER:
FOR: "Industrial Method for Producing :
Heterologous Proteins in E. Coli :
And Strains Useful For Said Method" :

Assistant Commissioner for Patents
Box PCT
Washington, D.C. 20231

"Express Mail" No.: EE617838829

Date: December 7, 2000

I hereby certify that this paper, along with any other paper or fee referred to in this paper as being transmitted herewith, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, postage prepaid, on the date indicated above, addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231

Jean Marshall
(Typed or printed name of mailing paper or fee)


(Signature of person mailing paper)

**TRANSMITTAL OF APPLICATION PAPERS
TO U.S. DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. §371
(CFR 1.494 OR 1.495)**

This Transmittal Letter is based upon PTO Form 1390 (as revised in May, 1993).

The above-identified applicant(s) (jointly with their assignee) have filed an International Application under the P.C.T. and hereby submit(s) to the United States

Designated/Elected Office (DO/EO/US) the following items and other information.

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. §371[f]) at any time rather than delay.
4. ☒ A proper Demand for International Preliminary Examination (IPE) was made to the appropriate Authority (IPEA) within the time period required.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371[c][2]) --
 - a. ☒ is transmitted herewith (required when not transmitted by International Bureau) with (4) sheets of Drawings and (5) sequence listing sheets. See WIPO Publication WO 99/64607.
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A (verified) translation of the International Application into the English language.
7. ☐ Amendments to the (specification and) claims of the International Application under PCT Article 19 (35 U.S.C. 371[c][3])
 - a. ☐ are transmitted herewith (required if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
 - e. ☐ will be submitted with the appropriate surcharge.
8. ☐ A translation of the amendments to the claims (and/or the specification) under PCT Article 19 (35 U.S.C. §371[c][3]) is enclosed or will be submitted with the appropriate surcharge.
9. ☐ An oath or declaration/power of attorney of the inventor(s) (35 U.S.C.

§371[c][4]) is enclosed

☐ and is attached to the translation of (or a copy of) the International Application.

☐ and is attached to the substitute specification.

10. ☒ A translation of at least the Annexes to the IPE Report under PCT Article 36 (35 U.S.C. §371[c][5]) is enclosed.

Items 11. to 16. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98 is enclosed.
12. ☐ An Assignment is enclosed for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31.
13. ☒ A FIRST preliminary amendment is enclosed.
A SECOND or SUBSEQUENT preliminary amendment is enclosed.
14. ☐ A substitute specification (including claims, abstract, drawing) is enclosed.
15. ☐ A change of power of attorney and/or address letter is enclosed.
16. ☒ Other items of information:

☒ This application is being filed pursuant to 37 CFR 1.494(c) or 1.495(c), and any **missing parts** will be filed before expiration of--

☐ 22 months from the priority date under 37 CFR 1.494(c), or

☒ 32 months from the priority date under 37 CFR 1.495(c).

☒ The undersigned attorney is authorized by the International applicant and by the inventors to enter the **National Phase** pursuant to 37 CFR 1.494(c) or 1.495(c).

The following additional information relates to the International Application:

International Application No. PCT/FR99/01343

09719009/712017
PH-98/032
528 Rec'd PCT/PTO 07 DEC 2000

- ☒ Receiving Office: FR
- ☒ IPEA (if filing under 37 CFR 1.495): EPO
- ☒ Priority Claim(s) (35 USC §§ 119, 365):
French Application 98/07474 filed - June 10, 1998

- ☒ A copy of the International Search Report is
 - ☐ enclosed.
 - ☒ attached to the copy of the International
Application with English translation.

- ☒ A copy of the Receiving Office Request Form is enclosed (with English
translation).

- ☒ Form PCT/IB/304 1-sheet
- ☒ Form PCT/IB 332 1-sheet
- ☒ Form PCT/IPEA/416 and 409 (12 sheets (In French))
- ☒ Form PCT/IB/304 4-sheets

The fee calculation is set forth on the next page of this Transmittal Letter.

FEE CALCULATION SHEET

[X] A check in payment of the filing fee, calculated as follows, is attached (37 CFR 1.492).

Basic Fee.....	\$ 860.00
Total Number of claims in excess of (20) times \$18.....	-0-
Number of independent claims in excess of (3) times \$80.....	-0-
Fee for multiple dependent claims \$270.....	-0-

TOTAL FILING FEE...\$860.00

Kindly send us the official filing receipt.

The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Deposit Account No. 03-2775. This is a "general authorization" under 37 CFR 1.25(b), except that no automatic debit of the issue upon allowance is authorized. An additional copy of this page is attached.

Respectfully submitted,

By Christine M. Hansen

Christine M. Hansen
Reg. No. 40,634
CONNOLLY BOVE LODGE & HUTZ, LLP
1220 Market Street
P.O. Box 2207
Wilmington, Delaware 19899
Tel. (302) 658-9141

CMH/jm (5500*54)

Enclosures

ODMA\MHODMA\CB,120949,1

097190109/718017
528 Rec'd PCT/PTO 07 DEC 2000

Atty. Docket #: PH-98/032

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INTERNATIONAL APPL. NO.: PCT/FR99/01343 :
INTERNATIONAL FILING DATE: June 8, 1999 :
APPLICANT: Jerome Pierrard et al :
SERIAL NO: : ART UNIT:
FILED: Herewith : EXAMINER:
FOR: "Industrial Method for Producing :
Heterologous Proteins in E. Coli :
And Strains Useful For Said Method" :

Assistant Commissioner for Patents
Box PCT
Washington, D.C. 20231

"Express Mail" No.: EE617838829

Date: December 7, 2000

I hereby certify that this paper, along with any other paper or fee referred to in this paper as being transmitted herewith, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, postage prepaid, on the date indicated above, addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231

Jean Marshall

(Typed or printed name of mailing paper or fee)


(Signature of person mailing paper)

PRELIMINARY AMENDMENT

Sir:

Prior to any action on the merits of the accompanying new patent application, please
amend the application as follows:

In the Claims:

Please amend Claims 4, 5, 7, 9, 10, 12-14 and 16 without prejudice as follows:

PH-98/032

Claim 4, line 1, delete "one of claims 1 to 3" and replace with - - claim 1 - -;
Claim 5, line 1, delete "one of claims 1 to 4" and replace with - - claim 1 - -;
Claim 7, line 1, delete "one of claims 1 to 6" and replace with - - claim 1 - -;
Claim 9, line 1, delete "either of claims 7 and 8" and replace with - - claim 7 - -;
Claim 10, line 1, delete "one of claims 1 to 9" and replace with - - claim 1 - -;
Claim 12, line 1, delete "either of claims 9 and 10" and replace with - - claim 9 - -;
Claim 13, line 1, delete "one of claims 10 to 12" and replace with - - claim 10 - -;
Claim 14, line 1, delete "one of claims 1 to 13" and replace with - - claim 1 - -;
Claim 16, line 1, delete "one of claims 1 to 15" and replace with - - claim 1 - -.

REMARKS

By this Preliminary Amendment any and all multiple dependencies are eliminated.

Respectfully submitted,

CONNOLLY BOVE LODGE & HUTZ LLP

By Christine M. Hansen
Christine M. Hansen
Registration No. 40,634
P.O. Box 2207
Wilmington, DE 19899
(302) 888-6432
Attorney for Applicants

CMH/jm (5500*54)
::ODMA\HODMA\CB,121099,1

101 Rec'd PCT/PTO 05 MAR 2001

09/719017

Atty. Docket #: PH-98/032

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jerome Pierrard et al. :
SERIAL NO: 09/719,017 : ART UNIT:
FILING DATE: December 7, 2000 : EXAMINER:
FOR: "Industrial Method for Producing :
Heterologous Proteins in E. Coli :
And Strains Useful For Said Method" :

Commissioner for Patents
Washington, D.C. 20231

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, WASHINGTON D.C. 20231 ON
THIS 27th DAY OF February 2001.

BY:

Jean H. Marshall

SECOND PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the Specification:

At page 12, line 21, please replace "[lacuna]" with - -acid- -.

At page 17, line 3, please replace "reoresents" with - -represents- -.

At page 18, line 19, please replace "conting" with - -counting- -.

In the Claims:

Please cancel claims 1-20 without prejudice or disclaimer, and please add new claims 21-
44 as follows:

- -21. An industrial process for preparing a heterologous protein, comprising:

- (1) introducing a suitable system for expressing heterologous proteins into an *E. coli*
bacteria strain W host cell; and

SERIAL NO: 09/719,017

PH-98/032 (5500*54)

- (2) seeding and culturing the *E. coli* bacteria strain W host cell in a suitable culture medium; such that the industrial process produces the heterologous protein.
22. The process of claim 21, wherein the *E. coli* bacteria strain W host cell is from the strain designated ATCC Number 9637.
23. The process of claim 21, wherein the *E. coli* bacteria strain W host cell is a derivative of the strain designated ATCC Number 9637 and is obtained by clonal selection or genetic manipulation.
24. The process of claim 21, wherein the suitable culture medium is a culture medium suitable for production of a high density of biomass and a high content of heterologous proteins produced.
25. The process of claim 21, wherein the suitable culture medium has a volume of greater than two liters.
26. The process of claim 21, wherein the suitable culture medium comprises L-tryptophan.
27. The process of claim 26, wherein L-tryptophan is present in the suitable culture medium at between 0.05 and 0.5 g/l.
28. The process of claim 27, wherein L-tryptophan is present in the suitable culture medium at between 0.1 and 0.3 g/l.
29. The process of claim 21, wherein the suitable culture medium comprises sucrose as the main carbon source.
30. The process of claim 29, wherein the suitable culture medium comprises substantially only sucrose as a carbon source.

SERIAL NO: 09/719,017

PH-98/032 (5500*54)

31. The process of claim 29, wherein the amount of sucrose in the suitable culture medium is between 0.1 and 300 g/l at the start of culturing.
32. The process of claim 31, wherein the amount of sucrose in the suitable culture medium is between 0.5 and 200 g/l at the start of culturing.
33. The process of claim 21, wherein the suitable culture medium comprises a supplementary organic nitrogen source.
34. The process of claim 33, wherein the supplementary organic nitrogen source consists of protein extracts.
35. The process of claim 34, wherein the protein extracts comprise, in g amino acids per 100 g of product, alanine between 10 and 4, aspartic acid between 11 and 4, glycine between 22 and 2.5, and lysine between 7 and 4.
36. The process of claim 33, wherein the supplementary organic nitrogen source consists essentially of meat or potato peptones or proteins.
37. The process of claim 33, wherein the supplementary organic nitrogen source consists essentially of derivatives of potato proteins.
38. The process of claim 21, wherein the suitable system for expressing heterologous proteins comprises a P_{irp} promoter.
39. The process of claim 38, wherein the P_{irp} promoter comprises the nucleic acid sequence of SEQ ID NO: 1.
40. The process of claim 21, wherein the heterologous protein is an enzyme.
41. The process of claim 40, wherein the enzyme is useful for the biocatalysis of chemical

4/PRTS

WO 99/64607

PCT/FR99/01343

1

INDUSTRIAL PROCESS FOR PRODUCING HETEROLOGOUS PROTEINS
IN *E. COLI* AND STRAINS USEFUL FOR SAID PROCESS

The present invention relates to a novel
5 industrial process for producing heterologous proteins
in *E. coli*. While for certain heterologous proteins
with very high added value the cost price of the
process for preparing them remains a factor which is
negligible with compared to the purpose of the
10 heterologous protein (in the pharmaceutical domain in
particular), the development of the industrial
production of heterologous proteins of lower added
value in *E. coli* involves taking into account
production factors such as the necessity of having an
15 increased biomass and a very high content of
heterologous proteins produced for the lowest possible
cost, which cost should take account of the nature of
the media, of the energetic and reagent yield and of
the operating conditions. For industrial productions
20 using reaction volumes which can reach several dozens
of m³, the simplest possible media and operating
conditions will be sought. The present invention
consists of the selection of an *E. coli* strain suitable
for satisfying the conditions above, which are
25 essential for economically satisfactory industrial

WO 99/64607

PCT/FR99/01343

2

production of heterologous proteins, independently of the value of the protein produced.

The strains of *E. coli* most commonly used for molecular biology studies derive from the strain K12 (Swartz. 1996, In *Escherichia coli* and *Salmonella*, Cellular and Molecular Biology, 2nd edition, ASM Press Washington, pp. 1693-1711). Derivatives of *E. coli* B, such as BL21, are also used for producing proteins, because of their physiological properties. A table of the strains most commonly used for producing recombinant proteins is given by Wingfield, 1997 (Current Protocols in Protein Science, Coligan et al. Ed. John Wiley & Sons, Inc. 5.0.1-5.0.3).

Many systems for expressing proteins in bacterial hosts have been described (Makrides, 1996, Microbiol. Rev. 60:512-538; Current Opinions in Biotechnology, 1996, 7). An expression system consists of a promoter, of its regulator, of a ribosome binding site followed by a restriction site which allows the insertion of the gene of interest, of a structure which can be used as a transcription terminator, optionally of genes the coexpression of which increases the quality of the protein of interest overexpressed, and of one or more vectors which make it possible to introduce these combinations into the host.

WO 99/64607

PCT/FR99/01343

3

The promoter must have at least three properties in order to be used in a process for producing proteins (Makrides, 1996, mentioned above):

- it must be strong and cause the accumulation of the protein of interest, which can represent 10 to 50% of the total proteins of the host cell;
- it must be capable of being regulated so as to be able, as far as possible, to uncouple the biomass production phase from the protein production phase;
- it must be inducible (passage from a level of low transcriptional activity to a maximum level of transcriptional activity) using simple and inexpensive process conditions.

Many promoters have been described for expression in *E. coli* (Makrides, 1996, mentioned above; Weickert et al., 1996, Current Opinions in Biotechnology 7 : 494-499). Among the homologous promoters used for producing proteins in *E. coli*, mention may be made of the *lac*, *trp*, *lpp*, *phoA*, *recA*, *araBAD*, *proU*, *cst-1*, *tetA*, *cadA*, *nar*, *tac*, *trc*, *lpp-lac*, *Psyn* and *cspA* promoters. Among the heterologous promoters used for producing proteins in *E. coli*, mention may be made of the *PL*, *PL-9G-50*, *PR-PL*, *T7*, λ *PL-PT7*, *T3-lac*, *T5-lac*, *T4 gene 32*, *nprM-lac*, *VHb* and *Protein A* promoters. A certain number of drawbacks are linked to these promoters. For some of

WO 99/64607

PCT/FR99/01343

4

them, mention may be made of the use of IPTG as the inducer molecule, the price of which can represent more than 14% of the cost of the medium. Others use regulation by temperature, which is difficult to
5 implement on the scale of a 100 m³ industrial fermenter.

The vectors most commonly used for expressing proteins in *E. coli* derive from the plasmid pBR322 (Swartz, 1996, mentioned above; Makrides, 1996, mentioned above). They are present in cells at a
10 certain copy number, which is determined by the interaction of two RNAs encoded by the plasmid, RNAI and RNAII (Polisky, 1988, Cell 55 : 929-932). The interaction of RNAI with RNAII inhibits the maturation of RNAII into a form required for the initiation of the
15 replication of the plasmid. This interaction is modulated by the protein ROP, the gene of which is present on pBR322 but not on certain derivatives, such as the pUC-type plasmids (Lin-Chao and Cohen, 1991, Cell 65 : 1233-1242). With regard to regulation of the
20 number of copies of the expression plasmid in *E. coli*, several strategies are mentioned (Swartz, 1996, mentioned above; Makrides, 1996, mentioned above). It will be appreciated in particular that a high number of copies of expression plasmid leads to a high level
25 of messenger RNAs of the desired protein, but can be

WO 99/64607

PCT/FR99/01343

5

detrimental to the metabolism of the host cell (Bailey, 1993, Adv. Biochem. Eng. Biotechnol. 48 : 29-52).

The stability of the expression plasmids is an important criterion, all the more so given that industrial fermentations tend not to use antibiotics in the fermenters. Several strategies have been developed to stabilize expression plasmids, including the cloning of the *cer* locus of the natural plasmid ColE1. This locus has been characterized (Leung et al., 1985, DNA 4 : 351-355) and its insertion into multicopy plasmids has been described as having a beneficial effect on the stability of these plasmids (Summers and Sherratt, 1984, Cell 36 : 1097-1103).

While the strains and expression systems above make it possible to obtain good heterologous protein production yields, their use remains limited to the production of heterologous proteins with very high added value for which the cost price of the production system (bacterial strain, culture medium and conditions, raw materials) is minimal compared with the value of the protein produced. As examples of such proteins with very high added value, there are more particularly the heterologous proteins intended for pharmaceutical use, such as for example human growth factor, human alpha consensus interferon, human

WO 99/64607

PCT/FR99/01343

6

interleukins 1 β , α 1 and 2, human leukocyte interferon, human parathyroid hormone, human insulin, human serum albumin or human proapolipoprotein A-1 (Lee, 1996, Trends in Biotechnol. 14:98-105; Latta et al., 1987, 5 Bio/Technology 5 : 1309-1313).

However, for the mass production of chemical intermediates (Lee, 1997, Nature Biotech. 15 : 17-18) or for the production of enzymes for industrial use, in particular of the catalysts required for producing 10 chemical compounds, the cost price of the production system becomes a dominant factor to be taken into consideration in order to evaluate the technical advantage of said system.

For the production of heterologous proteins 15 in bacteria, the productivity of the culture system employed can be significantly increased by using high cell density culturing strategies (S. Makrides, 1996, mentioned above; Wingfield, 1997, mentioned above). Among these is the fed-batch strategy (Jung et al., 20 1988, Ann. Inst. Pasteur/Microbiol. 139 : 129-146; Kleman et al., 1996, Appl. Environ. Microbiol. 62 : 3502-3507; Lee, 1996, mentioned above; Bauer and White, 1976, Biotechnol. Bioeng. 18 : 839-846). This strategy, combined with the use of a *P_{trp}* promoter, has made it 25 possible to achieve significant productivities: 55 g of

WO 99/64607

PCT/FR99/01343

7

dry weight per liter, and 2.2 g of heterologous protein per liter (Jung et al., 1988, mentioned above). Routine productions of 35 to 50 g of dry weight per liter are reported (Wingfield, 1997, mentioned above).

5 However, the strains and systems above do not make it possible to obtain culture densities which are sufficient for the industrial production of heterologous proteins for which the value (cost price) must be negligible compared to their purpose (in
10 particular for the preparation of biological catalysts).

 The present invention lies in the selection of a specific strain of *E. coli*, which is suitable for the industrial production of heterologous proteins. The
15 strain which is useful for the process according to the invention is an *E. coli* strain W, more particularly the strain W referenced at the ATCC under the number 9637.

 This strain W (ATCC 9637) is well known, and described in many publications (Davies & Mingioli,
20 1950, J. Bact., 60: 17-28; Doy and Brown, 1965, Biochim. Biophys. Acta, 104: 377-389; Brown and Doy, 1966, Biochim. Biophys. Acta, 118: 157-172; Wilson & Holden, 1969, J. Biol. Chem., 244: 2737-2742; Wilson & Holden, 1969, J. Biol. Chem., 244: 2743-2749; White,
25 1976, J. Gen. Microbiol., 96: 51-62; Shaw & Duncombe,

WO 99/64607

PCT/FR99/01343

8

1963, Analyst 88: 694-701; Br. Pharmacopoeia, 1993, 2: A164-A169; Huang et al., US 3,088,880; Hamsher et al., US 3,905,868; Takahashi et al., US 3,945,888; Huang et al., US 3,239,427; Burkholder, 1951, Science, 114: 459-460; Prieto et al., 1996, J. Bact., 178: 11-120; Lee 1996, mentioned above; Lee & Chang, 1995, Can. J. Microbiol, 41: 207-215; Lee et al., 1994, Biotechnol. Bioeng., 44: 1337-1347; Lee & Chang, 1993, Biotechnology Letters. 15: 971-974; Bauer and White, 1976, mentioned above; Bauer and Shiloach, 1974, Biotechnol. Bioeng 16: 933-941; Gleiser and Bauer, 1981, Biotechnol. Bioeng., 23: 1015-1021; Lee and Chang, 1995, Advances in Biochem. Engine./Biotech. 52: 27-58). The strain W (ATCC9637) has thus been used for the production of 3-polyhydroxybutyric acid (PHA) after introduction of a plasmid carrying the operon of *Alcaligenes eutrophus* encoding enzymes involved in the PHA biosynthesis (Lee and Chang, 1993, mentioned above; Lee and Chang, 1995, mentioned above; Lee et al., 1994).

The strain W has also been used in high cell density cultures (Bauer and White, 1976, mentioned above; Bauer and Shiloach, 1974, mentioned above; Gleiser and Bauer, 1981, mentioned above; Lee and Chang, 1993, mentioned above; Lee et al., 1997,

WO 99/64607

PCT/FR99/01343

9

Biotechnology Techniques 11: 59-62). Biomasses of 125 g of dry weight per liter have thus been obtained (Lee and Chang, 1993, mentioned above) using sucrose as a carbon source.

5 However, this strain has never been described for the production of recombinant proteins. Furthermore, in combining a plasmid carrying the operon of *Alcaligenes eutrophus* encoding enzymes involved in PHA biosynthesis and a strategy of culturing the
10 corresponding recombinant strain W at high cell density, Lee and Chang (1993, mentioned above) obtained worse PHA productivity than with a strain XL1-Blue derived from the strain K12 (Lee and Chang, 1995, mentioned above; Lee, 1996, mentioned above).

15 The present invention relates, therefore, to an industrial process for preparing heterologous proteins in *E. coli*, in which *E. coli* bacteria modified with a suitable system for expressing heterologous proteins are seeded and cultured in a suitable culture
20 medium, characterized in that the strain of *E. coli* is an *E. coli* strain W. More preferably, the strain W is the strain W deposited at the ATCC under the number 9637.

 According to one particular embodiment of the
25 invention, the strain W is a derivative of the strain

WO 99/64607

PCT/FR99/01343

10

deposited at the ATCC under the number 9637, obtained by clonal selection or genetic manipulation.

According to the invention, the term "industrial process" is intended to mean any process in
5 which the bacterial culture volume is greater than the usual culture volume employed in research laboratories. Generally, the term "industrial process" is intended to mean any process for which the culture volume is greater than 2 liters, preferably greater than or equal
10 to 10 liters, more preferably greater than or equal to 20 liters, even more preferably greater than or equal to 50 liters. The process according to the invention is particularly suitable for culture volumes from several dozens of m³ up to more than 100 m³.

15 The suitable culture medium is a culture medium which is suitable for the production of a high density of biomass and a high content of heterologous proteins produced. Several types of medium (defined, complex and semidefined) can be used for high cell
20 density culturing (Lee, 1996, mentioned above). While the known media of the prior art, and in particular semidefined media, make it possible to accumulate good reproducibility of the composition of the medium and good productivity of the culture (Lee, 1996, mentioned
25 above), the development of such a medium requires,

WO 99/64607

PCT/FR99/01343

11

however, empirical optimization for taking into account the economic constraints set out previously (Lee, 1996, mentioned above).

According to one preferential embodiment of the invention, the culture medium comprises sucrose as the main carbon source. According to the invention, the expression "main carbon source" is intended to mean that the sucrose represents at least 50% by weight of the total weight of the carbon sources of the culture medium, more preferably at least 75% by weight, even more preferably at least 85% by weight. According to a more preferential embodiment of the invention, the culture medium comprises substantially only sucrose as a carbon source. It is understood that, for the process according to the invention, the culture medium can comprise suitable additives so as to increase the overall yield of the invention. These additives can have the ancillary function of behaving as a carbon source to the bacterial culture. However, these additives will not be considered as a carbon source for the purpose of the present invention if the *E. coli* W bacteria used in the process according to the invention cannot grow on said additives as the sole carbon source.

WO 99/64607

PCT/FR99/01343

12

Advantageously, the amount of sucrose in the culture medium of the process according to the invention is between 0.1 and 300 g/l at the start of culturing, (before seeding), preferably between 0.5 and 200 g/l. It is understood that, since the sucrose constitutes the main carbon source of the medium according to the invention, the amount of sucrose will be decreasing during the process. In general, at the end of the reaction, the amount of sucrose in the culture medium at the end of the reaction is between 0 and 10 g/l.

According to one advantageous embodiment of the invention, the suitable culture medium also comprises a supplementary organic nitrogen source. This supplementary organic nitrogen source can consist of all organic nitrogen sources known to a person skilled in the art. Preferably, the supplementary organic nitrogen source consists of protein extracts. These protein extracts have more preferably the following composition: (in g amino acids per 100 g of product) alanine between 10 and 4, aspartic [lacuna] between 11 and 4, glycine between 22 and 2.5 and lysine between 7 and 4. Meat or potato peptones or proteins satisfy such a profile, is/are particularly preferred for the

WO 99/64607

PCT/FR99/01343

13

particularly the derivatives of potato proteins are preferred.

According to the invention, the expression "suitable system for expressing heterologous proteins" is intended to mean any expression system comprising regulation elements suitable for the expression of heterologous proteins in *E. coli* W. These regulation elements comprise in particular promoters, ribosome binding sites and transcription terminators.

Advantageously, the expression system comprises a P_{trp} promoter. The P_{trp} promoter has been used in several examples (EP Application 0 198 745; CIP Application No. 08/194,588; Application WO 97/04083; Latta et al., 1987, Bio/Technology 5: 1309-1314; Denèfle et al., 1987, Gene 56: 61-70). In particular, Latta et al. (1990, DNA Cell. Biol. 9: 129-137) have conducted a detailed study on the influence of regulatory sequences upstream of the promoter, and of tandem-duplicated promoter sequences, and on the influence of the coexpression of the TrpR repressor. Their reference construct, pXL534, was used as a basis for the construction of pXL642 (CIP Application No. 08/194,588), used in the examples which illustrate the present invention. Preferably, the P_{trp} promoter

WO 99/64607

PCT/FR99/01343

14

comprises the nucleic acid sequence represented by
sequence identifier No. 1 (SEQ ID NO 1).

According to one embodiment of the invention,
in order to improve the level of expression of the
5 heterologous protein, a coexpression of the molecular
chaperones of *E. coli* GroESL (review by Makrides, 1996,
mentioned above) is carried out. The increase in the
intracellular concentration of the GroESL proteins
makes it possible, in effect, to assist the folding of
10 the recombinant protein and thus improve the level of
active protein (Weicker et al., 1996, Curr. Opin.
Biotechnol. 7: 494-499). The genes whose coexpression
promotes the expression of the heterologous protein
according to the invention, and its quality, are
15 included in the expression system according to the
invention.

According to the invention, the term
"heterologous protein" is intended to mean any protein
produced by the process according to the invention
20 which is not naturally found in *E. coli* W, in the
suitable expression system according to the invention.
It can be a protein of nonbacterial origin, for example
of animal, in particular human, or plant origin, or a
protein of bacterial origin which is not naturally
25 produced by *E. coli* W, or a protein of bacterial origin

WO 99/64607

PCT/FR99/01343

15

naturally produced by a bacterium other than *E. coli* W or a protein naturally produced by *E. coli* W, the expression of which is controlled by regulation elements different from those of the expression system according to the invention, or finally, a protein which
5 derives from the preceding ones after modification of certain elements of its primary structure.

Of course, the process according to the invention applies to any protein of interest the
10 production of which requires a great accumulation of proteins before either extracting them and purifying them, totally or partially, or using them in a mixture with the biomass which will have made it possible to produce them. It is the case, for example, of enzymes
15 which are useful for the biocatalysis of chemical reactions, and which can be used without a prior isolation and purification procedure, or also of enzymes which are used in the host bacterium in the process of growing, for the biotransformation of
20 chemical compounds.

Advantageously, the heterologous protein is an enzyme produced in industrial amounts for a subsequent use as a chemical reaction catalyst. According to one particular embodiment of the
25 invention, the enzyme is a nitrilase, advantageously a

WO 99/64607

PCT/FR99/01343

16

nitrilase of *Alcaligenes faecalis* (ATCC8750) described in patent application WO 98/18941 or a nitrilase of *Comamonas testosteroni* sp. described in CIP application No. 08/194,588, or an amidase such as those described
5 in applications WO 97/04083, EP 433 117 and EP 488 916, or a hydroxyphenylpyruvate dioxygenase described in application WO 96/38567.

The present invention also relates to an *E. coli* strain W as defined above, characterized in that
10 it comprises a system for expressing heterologous proteins, in which the promoter is the P_{trp} promoter defined above.

The examples hereinbelow make it possible to illustrate the present invention without, however,
15 seeking to limit the scope thereof.

The appended figures 1 to 3 represent maps of plasmids used in the various examples.

Figure 1 represents the map of the plasmid pRPA-BCAT41. The sites in brackets are sites which were
20 eliminated during cloning. P_{trp} : tryptophan promoter; nitB: nitrilase gene; TrrnB: transcription terminators; end ROP: end of the gene encoding the ROP protein (Chambers et al., 1988, Gene 68: 139-149); ORI: origin of replication; RNAI/II: RNAs involved in replication

WO 99/64607

PCT/FR99/01343

17

(Chambers et al., mentioned above); Tc: tetracyclin resistance gene.

Figure 2 reoresents 1 map of the plasmid pRPA-BCAT127. The sites between brackets have been
5 eliminated during cloning. Ptrp: tryptophan promoter; nitB: nitrilase gene; TrrnB: transcription terminators; ORI: origin of replication; RNAI^{*}/II: mutated RNAs involved in replication; Cm: chloramphenicol resistance gene; cer: cer locus.

10 Figure 3 represents the map of the plasmid pRPA-BCAT103. The sites between brackets have been eliminated during cloning. Sm/Sp: streptomycin and spectinomycin resistance gene; parABCDE: par locus (Roberts and Helinski, 1992, J. Bacteriol. 174: 8119-
15 8132); rep, mob, D20 and ori: regions involved in the replication and transfer of the plasmid (Scholtz et al., 1989, Gene 75: 271-288; Frey et al., 1992, Gene 113: 101-106).

Figure 4 represents the map of the plasmid
20 pRPA-BCAT126. Ptrp: tryptophan promoter; nitB: nitrilase gene; TrrnB: transcription terminators; ORI: origin of replication; RNAI^{*}/II: mutated RNAs involved in replication; Tc^r: tetracycline resistance gene; cer: cer locus.

WO 99/64607

PCT/FR99/01343

18

Figure 5 represents the map of the plasmid pRPA-BCAT143. Sm/Sp: streptomycin and spectinomycin resistance gene; rep, mob, and ori: regions involved in the replication and transfer of the plasmid (Scholtz et al., 1989, Gene 75: 271-288; Frey et al., 1992, Gene 113: 101-106); delta relates to the name of the deletion described in the text.

The techniques used are conventional molecular biology and microbiology techniques known to a person skilled in the art and described, for example, by Ausubel et al., 1987 (Current Protocols in Molecular Biology, John Wiley and Sons, New York), Maniatis et al., 1982, (Molecular Cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York), Coligan et al., 1997 (Current Protocols in Protein Science, John Wiley & Sons, Inc).

Example 1: Construction of the expression plasmids pBCAT29 and pBCAT41.

The 1.27 kb fragment containing the P_{trp} promoter, the ribosome binding site of the λ phage cII gene (RBS_{cII}) and the nitrilase gene of *Alcaligenes faecalis* ATCC8750 (*nitB*) was extracted from the plasmid pRPA6BCAT6 (application FR 96/13077) using the EcoRI and XbaI restriction enzymes, so as to be cloned into the vector pXL642 (described in CIP application

WO 99/64607

PCT/FR99/01343

19

No. 08/194,588) opened with the same restriction enzymes. The resulting plasmid, pRPA-BCAT15, was opened with the StuI and BsmI enzymes, and the 4.3 kb fragment was ligated with the purified 136 bp StuI-BsmI fragment of pRPA-BCAT4 (application FR 96/13077) so as to produce the plasmid pRPA-BCAT19. The partial sequencing of pRPA-BCAT19 confirmed the replacement of the codon of the Asp279 residue of the nitrilase with the codon of an Asn279 residue. The 1.2 kb EcoRI-XbaI fragment of pRPA-BCAT19 containing the *P_{trp}::RBScII::nitB* fusion was then cloned into the vector pRPA-BCAT28 opened with the same enzymes, so as to produce the 6.2 kb plasmid pRPA-BCAT29. The vector pRPA-BCAT28 was obtained by ligating the 3.9 kb SspI-ScaI fragment of pXL642 (CIP application No. 08/194,588) with the 2.1 kb SmaI fragment of pHP45ΩTc (Fellay et al., 1987, Gene 52: 147-154) in order to replace the ampicillin resistance marker with the tetracycline resistance marker. In destroying the NdeI site close to the origin of replication of the plasmid pRPA-BCAT29 by partial NdeI digestion and the action of *E. coli* Polymerase I (Klenow Fragment), a plasmid pRPA-BCAT41 was obtained, the map of which is represented in Figure 1. The sequence of the expression cassette is represented by sequence identifier No. 2 (SEQ ID NO 2).

WO 99/64607

PCT/FR99/01343

20

Example 2: Expression of the nitrilase of *A. faecalis* ATCC8750 in "batch" *E. coli* K12, BL21 and W.

The plasmids pRPA-BCAT29 and pXL2035 (Levy-Schill et al., 1995, Gene 161: 15-20) were introduced into the strains DH5 α (CLONECH. Product reference C1021-1), BL21 (Novagen, product reference 69386-1) and W (ATCC9637) of *E. coli* by conventional electroporation. Expression cultures were prepared as described in Example 5 of application FR 96/13077, reducing the preculture time to 8 hours and fixing the expression time at 16 hours. The biomasses after expression were estimated according to the optical density of the cultures, read at 660 nm (OD660), using the following equation: biomass in gram of dry weight per liter of culture = OD660 \times 0.35. The measurements of nitrilase activity of the cultures were carried out as described in application FR 96/13077. For each strain, two clones were analyzed and for each clone, the experiment was repeated. Table 1 contains, for each strain, the mean of the data obtained in the four experiments.

Table 1: Biomass and activities of the strains harboring the plasmids pRPA-BCAT29 and pXL2035

WO 99/64607

PCT/FR99/01343

21

STRAINS	BIOMASS (g/l)	ACTIVITY (U)	PRODUCTIVITY (P)
DH5 α	0.15	10.4	1.6
BL21	0.37	6.3	2.4
W	0.65	7.00	4.5

ABBREVIATIONS: g/l: gram of dry weight per liter of culture; U: kg of HMTBA formed per hour and per kg of dry weight; P: kg of HMTBA formed per hour and per liter of culture.

- 5 These data show that the strain W of *E. coli* (ATCC9637) is more effective at expressing the nitrilase NitB.

Example 3: Construction of pBCAT43.

- The polyamide hydrolase gene of *Comamonas*
 10 *acidovorans* N12 described in application WO 97/04083 (*pamII*) was cloned into the vector pBCAT41. This polyamide hydrolase gene was amplified by PCR in the form of a 1.26 kb DNA fragment, while introducing, in the PCR primers, the EcoRI and NcoI restriction sites
 15 in the 5' position of the gene and the XbaI restriction site in the 3' position. This fragment was then treated successively with the EcoRI enzyme and Mung Bean nuclease. After extraction of the proteins with phenol-chloroform-isoamyl alcohol, the treatment was continued
 20 with an XbaI digestion. Similarly, the vector pRPA-

WO 99/64607

PCT/FR99/01343

22

BCAT41 was opened with the NdeI enzyme, and then treated with Mung Bean nuclease. After extraction of the proteins with phenol-chloroform-isoamyl alcohol, the treatment was continued with an XbaI digestion.

- 5 After ligation of these two samples, the plasmid pRPA-BCAT43 was obtained: it contains the P_{trp} promoter and the RBS_{ScII} binding site separated from the translation start codon of the *pamII* gene by the sequence: AATACTTACACC.

10 **Example 4: Expression of the polyamidase PamII in "batch" *E. coli* DH5 α , BL21 and W.**

The plasmid pRPA-BCAT43 was introduced into the strains DH5 α , L21 and W of *E. coli* by conventional electroporation. Expression cultures were prepared as described in Example 2 above and varying the expression
15 time from 14 to 24 hours. The biomasses after expression were estimated as in example 2 above. The measurements of polyamide hydrolase activity of the cultures were carried out as described in application
20 WO 97/04083, with the following modifications:

- the cells were permeabilized with toluene by resuspending the cell pellets in a 100 mM tris-HCl, 5 mM EDTA, pH8, 1% toluene buffer so as to have a dry cell concentration of approximately 5 g/l; after
25 vigorous shaking, the suspension is incubated for one

WO 99/64607

PCT/FR99/01343

23

hour at 4°C and then centrifuged, and finally, the pellets of permeabilized cells are taken up in a 100 mM, pH7, phosphate buffer.

- the hydrolysis activity was measured on the AB
5 oligomer (one molecule of adipic acid condensed to one molecule of hexamethylenediamine) present at 2.5 g/l in the reaction medium containing 0.1 M potassium phosphate buffer at pH 7, and incubated at 30°C with stirring:
- 10 - 100 microliter samples are taken at regular intervals while adding to them the same volume of 0.2 N NaOH;
- the samples are analyzed by HPLC after ten-fold dilution in a solution of 50 mM H₃PO₄.

15 For each strain, from 1 to 24 clones were analyzed and for each clone, one to seven independent experiments were conducted. Table 2 contains, for each strain, the mean of the data obtained.

Table 2: Biomass and activities of the strains

20 harboring the plasmid pRPA-BCAT43

WO 99/64607

PCT/FR99/01343

24

STRAINS	NB CULTURES	ACTIVITY (U)	PRODUCTIVITY (P)
DH5a	11	0.77	0.3
BL21	3	1.4	1.8
W	24	2.1	2.6

ABBREVIATIONS: NB: number; U: g of AB hydrolyzed per hour and per g of dry weight; P: g of AB hydrolyzed per hour and per liter of culture.

These data show that the strain W (ATCC9637) of *E. coli* is more effective for expressing the PamII polyamidase.

Example 5: Construction and characterization of the plasmid pBCAT41-531.

The plasmid pRPA-BCAT41 underwent a mutagenesis step carried out with hydroxylamine as described in Miller 1992 (Mutagenesis. A short course in bacterial genetics. "A laboratory manual and handbook for *E. coli* and related bacteria", Cold Spring Harbor Laboratory Press, Unit 4, pp. 81-212) and Humphreys *et al.*, 1976 (Mol. Gen. Genet. 145: 101-108). Five micrograms of plasmid DNA purified on a cesium chloride gradient were incubated for 20 minutes at 80°C in a 50 mM sodium phosphate buffer, pH 6, containing 0.5 mM EDTA and 0.4 M NH₂OH. After the addition of an identical volume of 50 mM sodium phosphate buffer,

WO 99/64607

PCT/FR99/01343

25

pH 6, containing 0.5 mM EDTA, the reaction mixture was dialyzed against a large excess of 10 mM Tris-HCl buffer, pH 7.5, containing 1 mM EDTA and 100 mM NaCl. The plasmid DNA was then recovered by precipitation and approximately 20 ng of DNA was introduced by electroporation into the strain DH5 α harboring the plasmid pXL2035. Among the transformants obtained, one clone was selected because the productivity of the culture was 3 times higher than that of a culture of the strain DH5 α (pRPA-BCAT41, pXL2035). The plasmid pRPA-BCAT41-531 that it was harboring was extracted and reintroduced into a new DH5 α host harboring the plasmid pXL2035. Three clones were then analyzed under the conditions described in example 2, comparing them with 3 DH5 α clones (pRPA-BCAT41, pXL2035), and the results are given in table in Table 3.

Table 3: Biomass and activities of the strains harboring the plasmids pRPA-BCAT41, pRPA-BCAT41-531 and pXL2035

WO 99/64607

PCT/FR99/01343

26

Strains	Biomass (g/l)	Activity (U)	Productivity (P)
DH5 α (pRPA-BCAT41, pXL2035)	0.21	12	2.5
DH5 α (pRPA-BCAT41- 531, pXL2035)	0.63	12	7.5

ABBREVIATIONS: g/l: gram of dry weight per liter of culture; U: kg of HMTBA formed per hour and per kg of dry weight; P: kg of HMTBA formed per hour and per liter of culture.

5 These results indicate that the improvement in the productivity of the cultures is correlated with the presence of the plasmid pRPA-BCAT41-531.

10 The 1.27 kb EcoRI-XbaI fragment containing the $P_{trp}::nitB$ fusion was extracted from the plasmid pRPA-BCAT41 in order to be cloned in place of the one contained in pRPA-BCAT41-531. The resulting plasmid, pRPA-BCAT86, was introduced into the strain DH5a (pXL2035) and 3 transformants were studied under conditions similar to those described above. The

15 results are given in Table 4.

Table 4: Biomass and activities of the strains harboring the plasmids pRPA-BCAT41, pRPA-BCAT41-531, pRPA-BCAT86 and pXL2035

WO 99/64607

PCT/FR99/01343

27

Strains	Biomass (g/l)	Activity (U)	Productivity (P)
DH5 α (pRPA-BCAT41, pXL2035)	0.20	13.8	2.7
DH5 α (pRPA-BCAT41- 531, pXL2035)	0.68	11.0	7.4
DH5 α (pRPA-BCAT86, pXL2035)	0.69	11.9	8.1

ABBREVIATIONS: g/l: gram of dry weight per liter of culture; U: kg of HMTBA formed per hour and per kg of dry weight; P: kg of HMTBA formed per hour and per liter of culture.

5 The results show that the improvement in the productivity of the cultures harboring pRPA-BCAT41-531 is not due to an improvement in the specific activity of the strain, and that this improvement is not caused by a mutation in the fragment carrying the *P_{trp}* promoter
10 and the *nitB* gene.

**Example 6: Characterization of a mutation carried by the plasmid pBCAT41-531 responsible for the improvement in productivity of the cultures of strains
15 expressing nitrilase.**

The analysis of the amount of protein produced by the strains of example 5, by polyacrylamide

WO 99/64607

PCT/FR99/01343

28

gel electrophoresis in the presence of SDS, showed that all these constructs led to levels of nitrilase polypeptide synthesis which were comparable among the strains described in this example. On the other hand, preparations of plasmid DNA of pRPA-bCAT41 and pRPA-BCAT41-531 prepared from equivalent amounts of biomass demonstrated that the plasmid pRPA-BCAT41-531 is present at lower number of copies than its parent pRPA-BCAT41. The sequencing of the 994 bp region of pRPA-BCAT41-531, which stretches from the Tth111I site and covers the origin of replication of the plasmid, revealed two differences with respect to the sequence of the corresponding region of pBR322 (GeneBank #J01749, name: SYNpBR322). By referring to the numbering given in the sequence J01749 (0 is the middle of the unique EcoRI site), we found that an insertion of an A had taken place after base 2319, and that the C of position 3039 is replaced with a T, in pRPA-BCAT41-531. The first difference can be attributed to an error during the action of the Klenow polymerase which was used to destroy one of the NdeI sites of pRPA-BCAT29, and is located in a region which is not described as playing a role in the replication of pBR322 (Chambers et al., 1988, Gene 68: 139-149). The second error corresponds to a transition, a characteristic effect of

WO 99/64607

PCT/FR99/01343

29

hydroxylamine on DNA (Drake and Baltz, 1976, Annu. Rev. Biochem. 45: 11-37), and is located at the second nucleotide of the region transcribed into RNA I involved in the replication of pBR322 (Chambers *et al.*,
5 mentioned above). It is the latter mutation which is responsible for the lower number of copies of pRPA-BCAT41-531 in DH5 α and which is responsible for the better nitrilase productivity of the cultures of the strain DH5 α (pRPA-BCAT41-531, pXL2035).

10

Example 7: Expression of the nitrilase of *A. faecalis* ATCC 8750 in "fed-batch" (semicontinuous culture) *E. coli* BL21 and *E. coli* W.

The plasmids pRPa-BCAT41-531 and pXL2035 were
15 introduced by electroporation into the strains BL21 (reference mentioned above) and W (ATCC9637) so as to give the RPA-BIOCAT594 [BL21 (pRPA-BCAT41-531, pXL2035)] and RPA-BIOCAT714 [W (pRPA-BCAT41-531, pXL2035)] strains, respectively. The recombinants
20 *E. coli* BIOCAT 594 and *E. coli* BIOCAT 714 were cultured in 3.5 liter fermenters containing 2 liters of medium with the following composition:

WO 99/64607

PCT/FR99/01343

30

Compound	Concentration in g/l
KH_2PO_4	8
K_2HPO_4	6.3
$(\text{NH}_4)_2\text{SO}_4$	0.75
$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	2.5
Iron sulfate	0.04
$\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$	0.05
Manganese sulfate	0.01
Cobalt chloride	0.004
Zinc sulfate	0.002
Sodium molybdate	0.002
Copper chloride	0.002
Boric acid	0.0005
Citrate [lacuna].H ₂ O	1.7
Glucose monohydrate	95
L-tryptophan	0.1
Meat peptone	5
Yeast extract	3

The pH is maintained at 7.0 by adding aqueous ammonia. The oxygen saturation is maintained at 20% by adding air in a proportion of 1 volume/volume of medium/minute and by stirring. The glucose is introduced at the start at a final concentration of 2 g/l. After having been totally consumed, it is

REPLACEMENT SHEET (RULE 26)

WO 99/64607

PCT/FR99/01343

31

introduced continuously from a stock solution with the following composition: 700 g/l glucose; 19.6 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$. The rate of addition is 2.2 g of glucose/h.l of medium.

5 After fermentation for 24 hours, the medium is recovered and centrifuged, and the dry weight is estimated in g/l. The enzymatic activity is measured following a protocol given in patent WO 96/09403. It is expressed in kilos of ammonium 3-hydroxybutanoate formed
10 per hour and per kilo of dry cells.

Strain	Final biomass	Final activity	Yield on glucose
BIOCAT 594 (BL21)	27 g/l	13	23%
BIOCAT 714 (W)	40 g/l	17	40%

In this example, it appears clearly that the nitrilase is expressed much better in *E. coli* W than in
15 *E. coli* BL21, and that the recombinant *E. coli* W BIOCAT 714 grows much better than the recombinant *E. coli* BL21 BIOCAT 594.

Example 8: Influence of the organic nitrogen
20 **source of animal origin.**

WO 99/64607

PCT/FR99/01343

32

The E. coli strain W BIOCAT 714 is cultured in a 3.5 liter fermenter containing 2 liters of medium with the following composition:

Compound	Concentration in the medium in g/l
K_2HPO_4	8
$(NH_4)_2SO_4$	0.75
$MgSO_4 \cdot 7H_2O$	2.5
Iron sulfate	0.04
$CaCl_2 \cdot 2H_2O$	0.04
Manganese sulfate	0.026
Cobalt chloride	0.004
Zinc sulfate	0.013
Sodium molybdate	0.001
Copper chloride	0.001
Boric acid	0.00025
$AlCl_3$	0.00125
Citrate [lacuna]. H_2O	1.7
Glucose monohydrate	95
L-tryptophan	0.1
Yeast extract	3

5

The pH is maintained at 7.0 by adding aqueous ammonia. The oxygen saturation is maintained at 20% by

REPLACEMENT SHEET (RULE 26)

WO 99/64607

PCT/FR99/01343

33

adding air in a proportion of 1 volume/volume of medium/minute and by stirring. The glucose is introduced at the start at a final concentration of 2 g/l. After having been totally consumed, it is

5 introduced continuously from a stock solution with the following composition: 700 g/l glucose; 19.6 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$. The rate of addition is 2.2 g of glucose/h.l of medium.

An organic nitrogen source of animal origin

10 is added to this medium.

Organic nitrogen source of animal origin	Final biomass	Final activity	Yield on glucose
None	30	2	40%
2.5 g/l of meat peptone	33	12	40%
5 g/l of meat peptone	40	25	45%
5 g/l of casein	35	20	43%

The use of an increasing concentration of organic nitrogen of animal origin significantly

15 increases the specific activity of the cells.

WO 99/64607

PCT/FR99/01343

34

Example 9: Influence of the organic nitrogen of plant origin.

The culture conditions are identical to those of example 8. In this example, organic nitrogen of 5 plant origin is added.

Organic nitrogen source of animal origin	Final biomass	Final activity	Yield on glucose
None	30	2	40%
5 g/l of soybean peptone	31	4	40%
5 g/l of wheat peptone	32	5	40%
7.5 g/l of sodium hydrolysate of potato protein (Alburex SP; Roquette)	35	17	43%

The addition of plant organic nitrogen does not give identical results depending on the origin.

10 Surprisingly, the addition of potato protein gives as good a result as the organic nitrogen of animal origin.

WO 99/64607

PCT/FR99/01343

35

Example 10: Influence of the carbon source.

The E. coli strain W BIOCAT 714 is cultured in a 3.5 liter fermenter containing 2 liters of medium with the following composition:

Compound	Concentration in the medium in g/l
Corn-steep LAB2218 (Roquette)	40
Yeast extract	3
MgSO ₄ ·7H ₂ O	2.5

The pH is maintained at 7.0 by adding aqueous ammonia. The oxygen saturation is maintained at 20% by adding air in a proportion of 1 volume/volume of medium/minute and by stirring. The carbon source is introduced at the start at a final concentration of 2 g/l. After having been totally consumed, it is introduced continuously from a stock solution with the following composition: 700 g/l carbon source; 19.6 g/l MgSO₄·7H₂O. The rate of addition is 2.2 g of glucose or of sucrose/h.l of medium.

The carbon source is varied in this example.

WO 99/64607

PCT/FR99/01343

36

Carbon source	Final biomass	Final activity	Yield on carbon
Glucose monohydrate 90 g/l	38	11	45%
"Syrup zero" (EUROSUCRE) 90 g/l	38	17	45%

In this example, it is observed that the use of sucrose ("syrup zero") as a carbon source significantly increases the specific activity of the

5 cells.

Example 11: Construction of a plasmid for coexpression of the TrpR regulator

A 434 bp DNA fragment which carries the *trpR* gene and its promoter was extracted from the plasmid pRPG9 (Gunsalus and Yanofsky, 1980, Proc. Natl. Aca. Sci. USA 77: 7117-7121) using the AatII and StuI restriction enzymes. This fragment was cloned into the plasmid pSL301 (Brosius, 1989, DNA 8: 759-777) by

10 ligating it to the approximately 3.1 kb AatII-StuI fragment, so as to give the plasmid pRPA-BCAT30. The *trpR* gene and its promoter were then extracted from pRPA-BCAT30 in the form of a 475 bp EcoRI-NotI fragment in order to be cloned into the plasmid pXL2035 in place

15

WO 99/64607

PCT/FR99/01343

37

of a 240 bp EcoRI-NotI fragment. The resulting plasmid, pRPA-BCAT34, is therefore a derivative of pKT230 which allows the expression of the GroESL chaperones and of the TrpR regulator.

5

Example 12: Influence of the coexpression of GroESL and of TrpR.

The plasmid pRPA-BCAT34 was introduced by electroporation into the strains DH5 α (pRPA-BCAT29), BL21 (pRPA-BCAT29) and W (pRPA-BCAT29). Expression cultures of various strains were prepared as described in example 2, and the results are given in Table 5.

Table 5: Biomass and activities of the strains
 15 harboring combinations the plasmids pRPA-BCAT29, pXL2035 and pRPA-BCAT34

Combinations	pRPA-BCAT29		pRPA-BCAT29 pXL2035		pRPA-BCAT29 pRPA-BCAT34	
	U	P	U	P	U	P
DH5-alpha	0.37	0.16	10.4	1.6	2.0	0.7
BL21	0	0.0	6.4	2.4	5.6	2.0
W	1.7	0.96	7.0	4.5	8.9	6.5

WO 99/64607

PCT/FR99/01343

38

ABBREVIATIONS: U: activity, kg of HMTBA formed per hour and per kg of dry weight; P: productivity, kg of HMTBA formed per hour and per liter of culture.

5 The results show that the coexpression of GroESL makes it possible to increase the productivity of the cultures whatever the strain under consideration, by improving the specific activity of the cultures. This effect is correlated with an
10 increase in the solubility of the nitrilase polypeptide, as shown by an analysis of the proteins by electrophoresis as described in application FR 96/13077. The effect of the coexpression of the TrpR
15 makes it possible, in W, to improve the productivity of the cultures.

Example 13: Influence of the presence of a cer locus on pRPA-BCAT41

20 The 382 bp HpaII fragment containing the cer locus of the plasmid ColE1 (Leung et al., 1985, DNA 4: 351-355) was cloned into the replicative form of the M13mp7 phage at one of the 2 AccI sites. The construct obtained then made it possible to extract, with the
25 EcoRI enzyme, an approximately 430 bp fragment

WO 99/64607

PCT/FR99/01343

39

containing the *cer* locus, which was cloned into
 pRPA-BCAT41 at the *EcoRI* site, thereby producing the
 plasmid pRPA-BCAT66. This plasmid was introduced by
 electroporation into the strain W harboring the plasmid
 5 pRPA-BCAT34. Expression cultures of various strains
 were prepared as described in example 2, extending the
 duration of the expression cultures to 24 hours and
 studying three clones of each strain in a sole
 experiment. The mean results are given in Table 6.

10

Table 6: Biomass and activities of the strains
 harboring the plasmids pRPA-BCAT41, pRPA-BCAT66 and
 pRPA-BCAT34

Strains	Biomass (g/l)	Activity (U)	Productivity (P)
W (pRPA-BCAT41, pRPA-BCAT34)	2.1	6.9	14.5
DH5 α (pRPA-BCAT66, pRPA-BCAT34)	1.8	10.0	18.0

15 ABBREVIATIONS: g/l: gram of dry weight per liter of
 culture; U: kg of HMTBA formed per hour and per kg of
 dry weight; P: kg of HMTBA formed per [lacuna]

WO 99/64607

PCT/FR99/01343

40

These results show that adding the *cer* locus to the plasmid for expression of the nitrilase leads to an improvement in the productivity of the cultures.

5 **Example 14: Construction of the plasmid**

pRPA-BCAT127

After elimination of the unique NdeI site of the plasmid pRPA-BCAT30 by digestion and formation of blunt ends with polymerase I (Klenow fragment), the
10 *trpR* gene was extracted from this latter plasmid in the form of an approximately 300 bp fragment prepared by treatment with the AatII enzyme followed by the action of polymerase I (Klenow fragment), and then, after inactivation of the reaction mixture, by digestion with
15 the SacII enzyme. This fragment was cloned into the pRPA-BCAT66 plasmid after opening this plasmid with Tth111 followed by treatment with polymerase I Klenow fragment) and, after inactivation, with SacII. The plasmid pRPA-BCAT82 was thus obtained. Its origin of
20 replication was replaced with that of the plasmid pRPA-BCAT41-531 by replacing the approximately 1.12 kb Bst1107I-Eam1105I fragment. The construct selected during this cloning, the plasmid pRPA-BCAT99, has an artefact which is in the form of a deletion of one
25 nucleotide at the Eam1105I site, transforming this site

WO 99/64607

PCT/FR99/01343

41

into a unique PshAI site. The resistance marker of the plasmid pRPA-BCAT99 was then changed by cloning, between the AatII and PshAI sites, an approximately 1.07 kb AatII-PshAI fragment prepared after PCR amplification of the gene encoding chloramphenicol resistance from the matrix pACYC184 (New England Biolabs #401-M), using the primers Cm1 and Cm2, the sequence of which is:

Cm1 : 5'-CCCCCGACAGCTGTCTTGCTTTCGAATTTCTGCC

10 Cm2 : 5'-TTGACGTCAGTAGCTGAACAGGAGGG

The plasmid thus obtained was called pRPA-BCAT123. It was then modified by eliminating the *trpR* gene in the form of an approximately 0.525 kb SacI-Bst1107I fragment, and reclosing the plasmid after forming blunt ends with the Pfu polymerase (15 minutes at 75°C in the buffer recommended by the manufacturer Stratagène, and in the presence of 0.2 mM of deoxynucleotides). The plasmid thus obtained is the plasmid pRPA-BCAT127, the map of which is represented schematically in Figure 2.

20

**Example 15: Construction of the plasmids
pRPA-BCAT98 and pRPA-BCAT103.**

The plasmid pRPA-BCAT37, described in application FR 96/13077, was modified by replacing the approximately 3.2 kb SfiI-ScaI fragment with the

25

WO 99/64607

PCT/FR99/01343

42

approximately 2.42 kb SfiI-ScaI fragment of the plasmid RSF101D20 (Frey *et al.*, 1992, Gene 113: 101-106). This fragment contains a deletion in the 5' portion of the gene encoding the RepB primase, and reduces the frequency of transfer of the plasmid by 6 logs (Frey *et al.*, mentioned above). The plasmid thus obtained, pRPA-BCAT98, has several advantages: the loss of its mobilization functions makes it comply with the rules of industrial biosafety while at the same time retaining its properties of replication in Gram-negative bacteria.

The *par* locus (Gerlitz *et al.*, 1990, J. Bacteriol 172: 6194-6203) was then cloned on pRPA-BCAT98 as follows. The approximately 2.3 kb SphI-BamHI fragment of pGMA28 (Gerlitz *et al.*, mentioned above) was first cloned into the vector pUC18, thereby allowing its extraction in the form of a HindIII-EcoRI fragment so as to clone it into the vector pMTL22 (Chambers *et al.*, 1988, Gene 68: 139-49). The HindIII site was then destroyed by HindIII digestion and Klenow treatment. An approximately 2.38 kb fragment was then extracted with the PstI and BglII enzymes so as to be cloned into the vector pXL2426 at the PstI and BamHI sites and to produce the vector pXL2572. The vector pXL2426 originates from the replacement of the 2.38 kb

WO 99/64607

PCT/FR99/01343

43

SfiI-EcoRV fragment of pXL2391 (application FR 96/13077) with the 1.47 kb SfiI-EcoRV fragment of RSF1010D20. The cloning on the plasmid pXL2572, at the NdeI and BamHI sites, of an approximately 0.960 bp NdeI-BamHI fragment of pRR71 (Weinstein et al., 1992, J. Bacteriol. 174: 7486-7489) made it possible to reconstitute the *par* locus as a whole on the plasmid pXL2573. This locus was then extracted from pXL2573 in the form of a 2.6 kb EcoRI-blunt end (after treatment with PstI and Klenow) fragment in order to be cloned on the plasmid pRPA-BCAT98 opened with EcoRI and SacI, the latter end having been treated with the Pfu polymerase. The resulting plasmid was called pRPA-BCAT103 and its map is represented schematically in Figure 3.

15

Example 16: Use of the plasmids pRPA-BCAT98, pRPA-BCAT103 and pRPA-BCAT127 for expressing the nitrilase in W.

The plasmids pRPA-BCAT127, pRPA-BCAT98, pRPA-BCAT103, pXL2035 and pXL2231 (application FR 96/13077) were introduced into the strain W of *E. coli* by electroporation, and expression cultures were prepared under the conditions described in example 2, using the following antibiotics: 12 µg/ml tetracycline for pXL2231, 50 µg/ml kanamycin for pXL2035, 100 µg/ml

25

WO 99/64607

PCT/FR99/01343

44

streptomycin for pRPA-BCAT98 and pRPA-BCAT103, and 20 µg/ml chloramphenicol for pRPA-BCAT127. For each combination of plasmids, two to three clones were analyzed, and the mean results are given in Table 7.

5

Table 7: Biomass and activities of the strains harboring the plasmids pRPA-BCAT41-531, pRPA-BCAT127, pRPA-BCAT98, pRPA-BCAT103, pXL2035 and pXL2231

Combination	Biomass (g/l)	Activity (U)	Productivity (P)
pBCAT127/pXL2231	1.43	4.9	7
pBCAT127/pBCAT103	1.75	7	12
pBCAT127/pBCAT98	1.72	11.2	19
pBCAT127/pXL2035	1.70	7.2	12
pBCAT41-531/pXL2035	1.36	5.9	8

10 ABBREVIATIONS: g/l: gram of dry weight per liter of culture; U: kg of HMTBA formed per hour and per kg of dry weight; P: kg of HMTBA formed per hour and per liter of culture

The combinations pRPA-BCAT127/pRPA-BCAT98 and
15 pRPA-BCAT127/pRPA-BCAT103 allow an at least equivalent productivity to be obtained, using plasmids which are in conformity with the European criteria for biosafety.

WO 99/64607

PCT/FR99/01343

45

Example 17: Construction of the plasmid**pRPA-BCAT126**

The resistance marker of the plasmid pRPA-BCAT99 described in example 14 was changed as follows. The vector was opened with the PshAI and AatII enzymes and then treated with the Pfu polymerase (5 min at 75°C in the buffer recommended by the manufacturer Stratagène, and in the presence of 0.2 mM of deoxynucleotides), and the approximately 3.95 kb fragment was extracted from an agarose gel using the Quiaex kit (Quiagen) [other systems for recovering DNA can also be used, in particular those of chromatographic type]. It was ligated according to a conventional process with the 1.32 kb HindIII-BsmI fragment extracted from the plasmid pBR322 (New England Biolabs, ref 303-3S), and then treated as above with the Pfu polymerase. Among the plasmids obtained, the plasmid containing the insert carrying the tetracyclin resistance gene oriented in the same direction of transcription as the cassette for expressing the nitrilase was named pRPA-BCAT111. This plasmid was then opened with the NsiI and BstZ17I enzymes and then treated with the Pfu polymerase, and religated in order to eliminate the 0.47 kb fragment carrying the *trpR*

WO 99/64607

PCT/FR99/01343

46

gene. The plasmid obtained was named pRPA-BCAT126, the map of which is represented in Figure 4,

Example 18: Construction of the plasmid

5 pRPA-BCAT143

The plasmid pRPA-BCAT98 described in example 15 was opened with the SfiI and ScaI enzymes in order to replace the 2.42 kb fragment carrying the deletion in the 5' portion of the gene encoding the RepB primase with the 2.96 kb SfiI-ScaI fragment extracted from the
10 plasmid RSF1010Δ18 carrying a 267 bp in-frame deletion in the 5' portion of the *repB* gene (Frey *et al.*, 1992, Gene 113: 101-106). The deletion introduced on pRPA-BCAT143 decreases the frequency of transfer of the
15 plasmid to 10^{-6} (Frey *et al.*, 1992, Gene 113: 101-106) and makes it comply with the demands of the rules of biosafety. Unlike the plasmid pRPA6BCAT98 described above, this novel plasmid conserves a copy number close to the unmodified plasmid pXL2035 (Lévy-Schill *et al.*,
20 1995, Gene 161: 15-20). It is represented in Figure 2.

Example 19: Use of the plasmids pRPA-BCAT126 and pRPA-BCAT143 for expressing the nitrilase in W

The plasmids pRPA-BCAT126, pRPA-BCAT127
25 (described above), pRPA-BCAT143, pRPA-BCAT98 and

WO 99/64607

PCT/FR99/01343

47

pXL2035 were introduced into the strain W of *E. coli* by electroporation, and expression cultures were prepared under the conditions described in example 2, using the following antibiotics: 12 µg/ml tetracycline for

5 pRPA-BCAT41-531 and pRPA-BCAT126, 50 µg/ml kanamycin for pXL2035, 100 µg/ml streptomycin for pRPA-BCAT98 and pRPA-BCAT143, and 20 µg/ml chloramphenicol for pRPA-BCAT127. For each combination of plasmids, two to three clones were analyzed, and the mean results are given in

10 Table 8.

Table 8: Biomass and activities of the strains harboring the plasmids pRPA-BCAT41-531, pRPA-BCAT126, pRPA-BCAT127, pRPA-BCAT98, pRPA-BCAT143 and pXL2035

15

Combination	Biomass (g/l)	Activity (U)	Productivity (P)
pBCAT41-531/pXL2035	2.3	9.5	22
pBCAT41-531/pBCAT143	2.5	8.9	22
pBCAT126/pXL2035	2.2	9.8	21
pBCAT126/pBCAT98	1.3	3.5	4.5
pBCAT126/pBCAT143	2.5	8.1	20
pBCAT127/pBCAT143	2.8	7.1	20

WO 99/64607

PCT/FR99/01343

48

ABBREVIATIONS: g/l: gram of dry weight per liter of culture; U: kg of HMTBA formed per hour and per kg of dry weight; P: kg of HMTBA formed per hour and per liter of culture

5 Unlike the plasmid pBCAT98, the combinations of the plasmid pRPA-BCAT143 with one of the plasmids pRPA-BCAT41-531, pRPA-BCAT127 or pRPA-BCAT126 make it possible to conserve the productivity of the cultures prepared with the strains harboring the plasmid

10 pXL2035.

WO 99/64607

PCT/FR99/01343

49

CLAIMS

1. Industrial process for preparing heterologous proteins in *E. coli*, in which *E. coli*
5 bacteria modified with a suitable system for expressing heterologous proteins are seeded and cultured in a suitable culture medium, characterized in that the strain of *E. coli* is an *E. coli* strain W.
2. Process according to claim 1,
10 characterized in that the strain W is the strain W deposited at the ATCC under the number 9637.
3. Process according to claim 1, characterized in that the strain W is a derivative of the strain deposited at the ATCC under the number 9637,
15 obtained by clonal selection or genetic manipulation.
4. Process according to one of claims 1 to 3, characterized in that the suitable culture medium is a culture medium which is suitable for the production of a high density of biomass and a high content of
20 heterologous proteins produced.
5. Process according to one of claims 1 to 4, characterized in that the culture medium comprises L-tryptophan.
6. Process according to claim 5,
25 characterized in that the amount of L-tryptophan in the

WO 99/64607

PCT/FR99/01343

50

culture medium is between 0.05 and 0.5 g/l, preferably between 0.1 and 0.3 g/l.

7. Process according to one of claims 1 to 6, characterized in that the culture medium comprises 5 sucrose as the main carbon source.

8. Process according to claim 7, characterized in that the culture medium comprises substantially only sucrose as a carbon source.

9. Process according to either of claims 7 10 and 8, characterized in that the amount of sucrose in the culture medium is between 0.1 and 300 g/l at the start of culturing, preferably between 0.5 and 200 g/l.

10. Process according to one of claims 1 to 9, characterized in that the suitable culture medium 15 also comprises a supplementary organic nitrogen source.

11. Process according to claim 10, characterized in that the supplementary organic nitrogen source consists of protein extracts.

12. Process according to either of claims 9 20 and 10, characterized in that the protein extract has the following composition: (in g amino acids per 100 g of product) alanine between 10 and 4, aspartic [lacuna] between 11 and 4, glycine between 22 and 2.5 and lysine between 7 and 4.

WO 99/64607

PCT/FR99/01343

51

13. Process according to one of claims 10 to 12, characterized in that the supplementary organic nitrogen source consists of meat or potato peptones or proteins, more particularly the derivatives of potato
5 proteins.

14. Process according to one of claims 1 to 13, characterized in that the suitable system for expressing heterologous proteins comprises a P_{trp} promoter.

10 15. Process according to claim 14, characterized in that the P_{trp} promoter comprises the nucleic acid sequence represented by sequence identifier no. 1 (SEQ ID NO 1).

15 16. Process according to one of claims 1 to 15, characterized in that the heterologous protein is an enzyme.

17. Process according to claim 16, characterized in that the enzyme is useful for the biocatalysis of chemical reactions.

20 18. Process according to claim 17, characterized in that the enzyme is a nitrilase.

19. *E. coli* strain W, characterized in that it comprises a system for expressing heterologous proteins, in which the promoter is the P_{trp} promoter.

WO 99/64607

PCT/FR99/01343

52

20. Strain according to claim 19,
characterized in that the P_{trp} promoter comprises the
nucleic acid sequence represented by sequence
identifier no. 1 (SEQ ID NO 1).

PCT

ORGANISATION MONDIALE DE LA PROPRIÉTÉ INTELLECTUELLE
Bureau international

DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITE DE COOPERATION EN MATIÈRE DE BREVETS (PCT)

(51) Classification internationale des brevets ⁶ : C12N 15/55, 9/78, 9/80, 15/71, 1/21, C12P 21/02 // (C12N 1/21, C12R 1:19)	A1	(11) Numéro de publication internationale: WO 99/64607 (43) Date de publication internationale: 16 décembre 1999 (16.12.99)
(21) Numéro de la demande internationale: PCT/FR99/01343 (22) Date de dépôt international: 8 juin 1999 (08.06.99) (30) Données relatives à la priorité: 98/07474 10 juin 1998 (10.06.98) FR (71) Déposant (pour tous les Etats désignés sauf US): RHONE-POULENC NUTRITION ANIMALE [FR/FR]; 42, avenue Aristide Briand, F-92160 Antony (FR). (72) Inventeurs; et (75) Inventeurs/Déposants (US seulement): PIERRARD, Jérôme [FR/FR]; 3, rue Hector Berlioz, F-69009 Lyon (FR). GUITTON, Carole [FR/FR]; 23, rue du Petit Montessuy, F-69009 Lyon (FR). FAVRE-BULLE, Olivier [FR/FR]; 113, rue Baraban, F-69003 Lyon (FR). (74) Mandataire: TETAZ, Franck; Rhône-Poulenc Agro, 14/20, rue Pierre Baizet, F-69009 Lyon (FR).		(81) Etats désignés: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, brevet ARIPO (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), brevet eurasién (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevet européen (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), brevet OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Publiée <i>Avec rapport de recherche internationale.</i> <i>Avant l'expiration du délai prévu pour la modification des</i> <i>revendications, sera republiée si des modifications sont</i> <i>reçues.</i>
(54) Title: INDUSTRIAL METHOD FOR PRODUCING HETEROLOGOUS PROTEINS IN <i>E.COLI</i> AND STRAINS USEFUL FOR SAID METHOD (54) Titre: PROCEDE INDUSTRIEL DE PRODUCTION DE PROTEINES HETEROLOGUES CHEZ <i>E. COLI</i> ET SOUCHES UTILES POUR LE PROCEDE (57) Abstract The invention concerns an industrial method for preparing heterologous proteins in <i>E.coli</i> , which consists in seeding and cultivating in an appropriate culture medium <i>E.coli</i> bacteria modified with an appropriate system for expressing heterologous proteins, characterised in that the <i>E.coli</i> strain is an <i>E.coli</i> W strain. (57) Abrégé La présente invention concerne un procédé industriel de préparation de protéines hétérologues dans <i>E.coli</i> , dans lequel onensemence et on cultive dans un milieu de culture approprié des bactéries <i>E.coli</i> modifiées avec un système d'expression de protéines hétérologues approprié, caractérisé en ce que la souche de <i>E.coli</i> est une souche <i>E.coli</i> W.		

WO 99/64607

PCT/FR99/01343

1

LIST OF SEQUENCES

(iii) NUMBER OF SEQUENCES: 4

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 121 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GAATTCCTG TTGACAATTA ATCATCGAAC TAGTTAACTA GTACGCAGCT TGGCTGCAGG 60
TCGACCTGCA GCCAAGCTTG GGCATACATT CAATCAATTG TTATCTAAGG AAATACTTAC 120
A 121

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 1793 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

20 (ix) CHARACTERISTIC:

- (A) NAME/KEY: CDS
(B) POSITION: 123..1190

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

WO 99/64607

PCT/FR99/01343

2

GAATTCCTG TTGACAATTA ATCATCGAAC TAGTTAACTA GTACGCAGCT TGGCTGCAGG	60
TCGACCTGCA GCCAAGCTTG GGCATACATT CAATCAATTG TTATCTAAGG AAATACTTAC	120
AT ATG CAG ACA AGA AAA ATC GTC CGG GCA GCC GEC GTA CAG GCC GCC	167
Met Gln Thr Arg Lys Ile Val Arg Ala Ala Ala Val Gln Ala Ala	
1 5 10 15	
TCT CCC AAC TAC GAT CTG GCA ACG GGT GTT GAT AAA ACC ATT GAG CTG	215
Ser Pro Asn Tyr Asp Leu Ala Thr Gly Val Asp Lys Thr Ile Glu Leu	
20 25 30	
GCT CGT CAG GCC CGC GAT GAG GGC TGT GAC CTG ATC GTG TTT GST GAA	263
Ala Arg Gln Ala Arg Asp Glu Gly Cys Asp Leu Ile Val Phe Gly Glu	
35 40 45	
ACC TGG CTG CCC GGC TAT CCC TTC CAC GTC TGG CTG GGC GCA CCG GCC	311
Thr Trp Leu Pro Gly Tyr Pro Phe His Val Trp Leu Gly Ala Pro Ala	
50 55 60	

WO 99/64607

PCT/FR99/01343

3

TGG TCG CTG AAA TAC AGT GCC CGC TAC TAT GCC AAC TCG CTC TCG CTG	359
Trp Ser Leu Lys Tyr Ser Ala Arg Tyr Tyr Ala Asn Ser Leu Ser Leu	
65 70 75	
GAC AGT GCA GAG TTT CAA CGC ATT GCC CAG GCC GCA CGG ACC TTG GGT	407
Asp Ser Ala Glu Phe Gln Arg Ile Ala Gln Ala Ala Arg Thr Leu Gly	
80 85 90 95	
ATT TTC ATC GCA CTG GGT TAT AGC GAG CGC AGC GGC GGC AGC CTT TAC	455
Ile Phe Ile Ala Leu Gly Tyr Ser Glu Arg Ser Gly Gly Ser Leu Tyr	
100 105 110	
CTG GGC CAA TGC CTG ATC GAC GAC AAG GGC CAG ATG CTG TGG TCG CGT	503
Leu Gly Gln Cys Leu Ile Asp Asp Lys Gly Gln Met Leu Trp Ser Arg	
115 120 125	
CGC AAA CTC AAA CCT ACA CAT GTT GAG CGC ACC GTG TTT GGT GAA GGT	551
Arg Lys Leu Lys Pro Thr His Val Glu Arg Thr Val Phe Gly Glu Gly	
130 135 140	
TAT GCC CGA GAT CTG ATT GTG TCC GAC ACC GAG CTG GGC CGC GTC GGT	599
Tyr Ala Arg Asp Leu Ile Val Ser Asp Thr Glu Leu Gly Arg Val Gly	
145 150 155	
GCC CTG TGC TGC TGC GAG CAC CTG TCC CCC TTG AGC AAG TAC GGC CTG	647
Ala Leu Cys Cys Trp Glu His Leu Ser Pro Leu Ser Lys Tyr Ala Leu	
160 165 170 175	
TAC TCC CAG CAC GAA GCC ATT CAC ATT GCC GCC TGG CCG TCC TTT TCG	695
Tyr Ser Gln His Glu Ala Ile His Ile Ala Ala Trp Pro Ser Phe Ser	
180 185 190	
CTG TAC AGC GAA CAG GCC CAT GCG CTC AGC GCC AAG GTG AAC ATG GCT	743
Leu Tyr Ser Glu Gln Ala His Ala Leu Ser Ala Lys Val Asn Met Ala	
195 200 205	
GCC TCG CAA ATC TAT TCG GTT GAA GGC CAG TGC TTT ACC ATC GCC GCC	791
Ala Ser Gln Ile Tyr Ser Val Glu Gly Gln Cys Phe Thr Ile Ala Ala	
210 215 220	
AGC AGT GTC GTC ACC CAG GAG ACA CTG GAC ATG CTG GAA GTA GGT GAA	839
Ser Ser Val Val Thr Gln Glu Thr Leu Asp Met Leu Glu Val Gly Glu	
225 230 235	
CAC AAC GCC TCC CTG CTG AAA GTG GGC GGC GGC AGT TCC ATG ATT TTT	887
His Asn Ala Ser Leu Lys Val Gly Gly Gly Ser Ser Met Ile Phe	
240 245 250 255	
GCG CCG GAC GGA CGC ACA TTG GCT CCC TAC CTG CCA CAC GAT GCC GAA	935
Ala Pro Asp Gly Arg Thr Leu Ala Pro Tyr Leu Pro His Asp Ala Glu	
260 265 270	
GGC CTG ATC ATT GCC GAT CTG AAC ATG GAA GAA ATT GCC TTC GCC AAG	983
Gly Leu Ile Ile Ala Asp Leu Asn Met Glu Glu Ile Ala Phe Ala Lys	
275 280 285	
GCG ATC AAC GAC CCT GTG GGC CAC TAC TCC AAA CCC GAG GCC ACC CGT	1031
Ala Ile Asn Asp Pro Val Gly His Tyr Ser Lys Pro Glu Ala Thr Arg	
290 295 300	

REPLACEMENT SHEET (RULE 26)

WO 99/64607

PCT/FR99/01343

4

CTG GTA CTG GAC CTG GGG CAC CGT GAG CCC ATG ACT CGG GTG CAT TCC	1079
Leu Val Leu Asp Leu Gly His Arg Glu Pro Met Thr Arg Val His Ser	
305 310 315	
AAA AGC GTG ATC CAG GAA GAA GCT CCC GAG CCG CAC GTG CAA AGT ACG	1127
Lys Ser Val Ile Gln Glu Glu Ala Pro Glu Pro His Val Gln Ser Thr	
320 325 330 335	
GCT GCG CCC GTC GCC GTC AGC CAG ACT CAG GAC TCG GAT ACG CTA CTG	1175
Ala Ala Pro Val Ala Val Ser Gln Thr Gln Asp Ser Asp Thr Leu Leu	
340 345 350	
GTG CAA GAA CCG TCC TGA CCCCCAAAAGA TGACAAGGCC CGGGCAAAC	1223
Val Gln Glu Pro Ser	
355	
GTCCGGGTCT TGATTCCTTC TGCGTCCCGG ATCCACTAGT TCTAGAGTCG ACCTGCAGGC	1283
ATGCAAGCTT GGGTCCCACC TGACCCCATG CCGAACTCAG AAGTGAAACG CCGTAGCGCC	1343
GATGGTAGTG TGGGGTCTCC CCATGCGAGA GTAGGGAAC	1403
AAAGGCTCAG TCGAAAGACT GGGCCTTTCG TTTTATCTGT TGTTCGTCG TGAACGCTCT	1463
CCTGAGTAGG ACAAATCCGC CGGGAGCGGA TTTGAACGTT GCGAAGCAAC GGCCCGGAGG	1523
GTGGCGGGCA GGACGCCCCG CATAAACTGC CAGGCATCAA ATTAAGCAGA AGGCCATCCT	1583
GACGGATGGC CTTTTTGGGT TTCTACAAAC TCTTCCTGTC GTCATATCTA CAAGCCATCC	1643
CCCCACAGAT ACGGTAACT AGCCTCGTTT TTGCATCAGG AAAGCAGCTA TGAACCACTC	1703
CTTAAAACCC TGGAACACAT TTGGCATTGA TCATAATGCT CAGCACATTG TATGTGCCGA	1763
AGACGAACAA CAATTACTCA ATGCCCGCGG	1793

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 35 base pairs
- (B) TYPE: nucleotide
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

- 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CCCCCGACA GCTGTCTTGC TTTCGAATTT CTGCC

35

REPLACEMENT SHEET (RULE 26)

WO 99/64607

PCT/FR99/01343

5

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs

(B) TYPE: nucleotide

5 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TTGACGTCAG TAGCTGAACA GGAGGG

26

SEQUENCE LISTING

<110> Pierrard, Jerome
 Guitton, Carole
 Favre-Bulle, Olivier

<120> Industrial Method For Producing Heterologous Proteins
 In E. coli And Strains Useful For Said Method

<130> 5500*54

<140> US 09/719,017

<141> 1999-06-08

<150> PCT/FR99/01343

<151> 1999-06-08

<150> FR 98/07,474

<151> 1998-06-10

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 121

<212> DNA

<213> Escherichia coli

<400> 1

```
gaattccctg ttgacaatta atcatcgaac tagttaacta gtacgcagct tggctgcagg 60
tcgacctgca gccaaagcttg ggcatacatt caatcaattg ttatctaagg aaatacttac 120
a                                                                    121
```

<210> 2

<211> 1793

<212> DNA

<213> Alcaligenes faecalis

<220>

<221> CDS

<222> (123)..(1190)

<400> 2

```
gaattccctg ttgacaatta atcatcgaac tagttaacta gtacgcagct tggctgcagg 60
tcgacctgca gccaaagcttg ggcatacatt caatcaattg ttatctaagg aaatacttac 120
```

```
at atg cag aca aga aaa atc gtc cgg gca gcc gcc gta cag gcc gcc      167
Met Gln Thr Arg Lys Ile Val Arg Ala Ala Ala Val Gln Ala Ala
      1              5              10              15
```

```
tct ccc aac tac gat ctg gca acg ggt gtt gat aaa acc att gag ctg      215
Ser Pro Asn Tyr Asp Leu Ala Thr Gly Val Asp Lys Thr Ile Glu Leu
      20              25              30
```

gct cgt cag gcc cgc gat gag ggc tgt gac ctg atc gtg ttt ggt gaa	263
Ala Arg Gln Ala Arg Asp Glu Gly Cys Asp Leu Ile Val Phe Gly Glu	
35 40 45	
acc tgg ctg ccc ggc tat ccc ttc cac gtc tgg ctg ggc gca ccg gcc	311
Thr Trp Leu Pro Gly Tyr Pro Phe His Val Trp Leu Gly Ala Pro Ala	
50 55 60	
tgg tcg ctg aaa tac agt gcc cgc tac tat gcc aac tcg ctc tcg ctg	359
Trp Ser Leu Lys Tyr Ser Ala Arg Tyr Tyr Ala Asn Ser Leu Ser Leu	
65 70 75	
gac agt gca gag ttt caa cgc att gcc cag gcc gca cgg acc ttg ggt	407
Asp Ser Ala Glu Phe Gln Arg Ile Ala Gln Ala Ala Arg Thr Leu Gly	
80 85 90 95	
att ttc atc gca ctg ggt tat agc gag cgc agc ggc ggc agc ctt tac	455
Ile Phe Ile Ala Leu Gly Tyr Ser Glu Arg Ser Gly Gly Ser Leu Tyr	
100 105 110	
ctg ggc caa tgc ctg atc gac gac aag ggc cag atg ctg tgg tcg cgt	503
Leu Gly Gln Cys Leu Ile Asp Asp Lys Gly Gln Met Leu Trp Ser Arg	
115 120 125	
cgc aaa ctc aaa cct aca cat gtt gag cgc acc gtg ttt ggt gaa ggt	551
Arg Lys Leu Lys Pro Thr His Val Glu Arg Thr Val Phe Gly Glu Gly	
130 135 140	
tat gcc cga gat ctg att gtg tcc gac acc gag ctg ggc cgc gtc ggt	599
Tyr Ala Arg Asp Leu Ile Val Ser Asp Thr Glu Leu Gly Arg Val Gly	
145 150 155	
gcc ctg tgc tgc tgg gag cac ctg tcc ccc ttg agc aag tac gcg ctg	647
Ala Leu Cys Cys Trp Glu His Leu Ser Pro Leu Ser Lys Tyr Ala Leu	
160 165 170 175	
tac tcc cag cac gaa gcc att cac att gcc gcc tgg ccg tcc ttt tcg	695
Tyr Ser Gln His Glu Ala Ile His Ile Ala Ala Trp Pro Ser Phe Ser	
180 185 190	
ctg tac agc gaa cag gcc cat gcg ctc agc gcc aag gtg aac atg gct	743
Leu Tyr Ser Glu Gln Ala His Ala Leu Ser Ala Lys Val Asn Met Ala	
195 200 205	
gcc tcg caa atc tat tcg gtt gaa ggc cag tgc ttt acc atc gcc gcc	791
Ala Ser Gln Ile Tyr Ser Val Glu Gly Gln Cys Phe Thr Ile Ala Ala	
210 215 220	
agc agt gtc gtc acc cag gag aca ctg gac atg ctg gaa gta ggt gaa	839
Ser Ser Val Val Thr Gln Glu Thr Leu Asp Met Leu Glu Val Gly Glu	
225 230 235	
cac aac gcc tcc ctg ctg aaa gtg ggc ggc ggc agt tcc atg att ttt	887
His Asn Ala Ser Leu Leu Lys Val Gly Gly Gly Ser Ser Met Ile Phe	
240 245 250 255	

00719017.030601

gcg ccg gac gga cgc aca ttg gct ccc tac ctg cca cac gat gcc gaa 935
 Ala Pro Asp Gly Arg Thr Leu Ala Pro Tyr Leu Pro His Asp Ala Glu
 260 265 270

ggc ctg atc att gcc gat ctg aac atg gaa gaa att gcc ttc gcc aag 983
 Gly Leu Ile Ile Ala Asp Leu Asn Met Glu Glu Ile Ala Phe Ala Lys
 275 280 285

gcg atc aac gac cct gtg ggc cac tac tcc aaa ccc gag gcc acc cgt 1031
 Ala Ile Asn Asp Pro Val Gly His Tyr Ser Lys Pro Glu Ala Thr Arg
 290 295 300

ctg gta ctg gac ctg ggg cac cgt gag ccc atg act cgg gtg cat tcc 1079
 Leu Val Leu Asp Leu Gly His Arg Glu Pro Met Thr Arg Val His Ser
 305 310 315

aaa agc gtg atc cag gaa gaa gct ccc gag ccg cac gtg caa agt acg 1127
 Lys Ser Val Ile Gln Glu Glu Ala Pro Glu Pro His Val Gln Ser Thr
 320 325 330 335

gct gcg ccc gtc gcc gtc agc cag act cag gac tcg gat acg cta ctg 1175
 Ala Ala Pro Val Ala Val Ser Gln Thr Gln Asp Ser Asp Thr Leu Leu
 340 345 350

gtg caa gaa ccg tcc tgaccccaaa agatgacaag gcccgggcaa actgtccggg 1230
 Val Gln Glu Pro Ser
 355

tcttgattcc ttctgcgtcc cggatccact agttctagag tcgacctgca ggcatgcaag 1290

cttgggtccc acctgacccc atgccgaact cagaagtgaac acgccgtagc gccgatggta 1350

gtgtgggggtc tccccatgcg agagtaggga actgccaggc atcaaataaaa acgaaaggct 1410

cagtcgaaaag actgggcctt tcgttttatac tgttgtttgt cgggtgaacgc tctcctgagt 1470

aggacaaatc cgccggggagc ggatttgaac gttgcgaagc aacggcccgg aggggtggcgg 1530

gcaggacgcc cgccataaac tgccaggcat caaattaagc agaaggccat cctgacggat 1590

ggccttttttg cgtttctaca aactcttctt gtcgtcatat ctacaagcca tccccccaca 1650

gatacggtaa actagcctcg tttttgcatac aggaaagcag ctatgaacca ctctttaaaa 1710

ccctggaaca catttggcac tgatcataat gctcagcaca ttgtatgtgc cgaagacgaa 1770

caacaattac tcaatgcccg cgg 1793

<210> 3

<211> 356

<212> PRT

<213> *Alcaligenes faecalis*

<400> 3

Met Gln Thr Arg Lys Ile Val Arg Ala Ala Ala Val Gln Ala Ala Ser

1

5

10

15

Pro Asn Tyr Asp Leu Ala Thr Gly Val Asp Lys Thr Ile Glu Leu Ala
 20 25 30

Arg Gln Ala Arg Asp Glu Gly Cys Asp Leu Ile Val Phe Gly Glu Thr
 35 40 45

Trp Leu Pro Gly Tyr Pro Phe His Val Trp Leu Gly Ala Pro Ala Trp
 50 55 60

Ser Leu Lys Tyr Ser Ala Arg Tyr Tyr Ala Asn Ser Leu Ser Leu Asp
 65 70 75 80

Ser Ala Glu Phe Gln Arg Ile Ala Gln Ala Ala Arg Thr Leu Gly Ile
 85 90 95

Phe Ile Ala Leu Gly Tyr Ser Glu Arg Ser Gly Gly Ser Leu Tyr Leu
 100 105 110

Gly Gln Cys Leu Ile Asp Asp Lys Gly Gln Met Leu Trp Ser Arg Arg
 115 120 125

Lys Leu Lys Pro Thr His Val Glu Arg Thr Val Phe Gly Glu Gly Tyr
 130 135 140

Ala Arg Asp Leu Ile Val Ser Asp Thr Glu Leu Gly Arg Val Gly Ala
 145 150 155 160

Leu Cys Cys Trp Glu His Leu Ser Pro Leu Ser Lys Tyr Ala Leu Tyr
 165 170 175

Ser Gln His Glu Ala Ile His Ile Ala Ala Trp Pro Ser Phe Ser Leu
 180 185 190

Tyr Ser Glu Gln Ala His Ala Leu Ser Ala Lys Val Asn Met Ala Ala
 195 200 205

Ser Gln Ile Tyr Ser Val Glu Gly Gln Cys Phe Thr Ile Ala Ala Ser
 210 215 220

Ser Val Val Thr Gln Glu Thr Leu Asp Met Leu Glu Val Gly Glu His
 225 230 235 240

Asn Ala Ser Leu Leu Lys Val Gly Gly Gly Ser Ser Met Ile Phe Ala
 245 250 255

Pro Asp Gly Arg Thr Leu Ala Pro Tyr Leu Pro His Asp Ala Glu Gly
 260 265 270

Leu Ile Ile Ala Asp Leu Asn Met Glu Glu Ile Ala Phe Ala Lys Ala
 275 280 285

Ile Asn Asp Pro Val Gly His Tyr Ser Lys Pro Glu Ala Thr Arg Leu
 290 295 300

Val Leu Asp Leu Gly His Arg Glu Pro Met Thr Arg Val His Ser Lys
 305 310 315 320

Ser Val Ile Gln Glu Glu Ala Pro Glu Pro His Val Gln Ser Thr Ala
 325 330 335

Ala Pro Val Ala Val Ser Gln Thr Gln Asp Ser Asp Thr Leu Leu Val
 340 345 350

Gln Glu Pro Ser
 355

<210> 4
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:Primer

<400> 4
 cccccgcaca gctgtcttgc ttctgaattt ctgcc 35

<210> 5
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:Primer

<400> 5
 ttgacgtcag tagctgaaca ggaggg 26

<210> 6
 <211> 12
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:linker

<400> 6
 aataattaca cc 12

WO 99/64607

PCT/FR99/01343

1/5




Fig. 1

WO 99/64607

PCT/FR99/01343

2/5




Fig. 2

WO 99/64607

PCT/FR99/01343

3/5




Fig. 3

WO 99/64607

PCT/FR99/01343

4/5




Fig 4

WO 99/64607

PCT/FR99/01343

5/5




Fig 5

101 Rec'd PCT/PTO 03 OCT 2001

"Express Mail" No.: ET284672953US Date: October 9, 2001
I hereby certify that this paper or fee is being deposited with the
United States Postal Service "Express Mail Post Office to Addressee"
under 37 CFR 1.10 on the date indicated above and is addressed to the
Commissioner for Patents, Box PCT, Washington, D.C. 20231

Dorothy L. Sciarra
(Typed or printed name) of
person mailing paper or fee)

Dorothy L. Sciarra
(Signature of person
mailing paper or fee)

Atty. Docket #: PH-98/032 (5500*54)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jerome Pierrard et al :

SERIAL NO: 09/719,017 : **ART UNIT:**

FILED: June 8, 1999 : **EXAMINER:**

FOR: "Industrial Method for Producing :
Heterologous Proteins in E. Coli :
And Strains Useful For Said Method" :

Commissioner for Patents
Box PCT
Washington, D.C. 20231

ASSOCIATE POWER OF ATTORNEY

Sir:

In the matter of the above-identified application, please recognize Liza D. Hohenschutz, Reg.
No. 33,712, as an associate attorney with full power to prosecute this application and conduct all
business in the Patent and Trademark Office connected therewith.

Respectfully submitted,
CONNOLLY BOVE LODGE & HUTZ LLP

Date: Oct. 9, 2001

By: Christine Hansen
Christine M. Hansen
Reg. No. 40,634
P.O. Box 2207
Wilmington, Delaware 19899
(302) 888-6420
Attorney for Applicants

COMBINED DECLARATION AND POWER OF ATTORNEY

Attorney Docket No.

PH 98/032 (5500*54)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

the specification of which

(check one) ☐ is attached hereto.

☒ was filed on December 7, 2000

was amended on _____
(if applicable)

was amended through _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)**Priority Claimed**

<u>FR9807474</u> (Number)	<u>France</u> (Country)	<u>10 June 1998</u> (Day/Month/Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<u>PCT/FR99/01343</u> (Number)	<u>WIPO</u> (Country)	<u>8 June 1999</u> (Day/Month/Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application No.) (filing date)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.




_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

In the matter of the above-identified application, please recognize Rudolf E. Hutz, Reg. No. 22,397; John D. Fairchild, Reg. No. 19,756; Harold Pezzner, Reg. No. 22,112; Richard M. Beck, Reg. No. 22,580; Paul E. Crawford, Reg. No. 24,397; Patricia Smink Rogowski, Reg. No. 33,791; Robert G. McMorrow, Jr., Reg. No. 30,962; Ashley I. Pezzner, Reg. No. 35,646; William E. McShane, Reg. No. 32,707; Mary W. Bourke, Reg. No. 30,982; Gerard M. O'Rourke, Reg. No. 39,794; James M. Olsen, Reg. No. 40,408; Francis DiGiovanni, Reg. No. 37,310; Eric J. Evain, Reg. No. 42,517; Daniel C. Mulveny, Reg. No. 45,897; Christine M. Hansen, Reg. No. 40,634; Patrick H. Higgins 39,709 and Elliot C. Mendelson (Agent), Reg. No. 42,878, all of P.O. Box 2207, Wilmington, Delaware 19899-2207 as attorneys with full power of substitution to prosecute this application and conduct all business in the Patent and Trademark Office connected therewith.

Send Correspondence To: Connolly Bove Lodge & Hutz LLP P.O. Box 2207 Wilmington, Delaware 19899-2207		Direct Telephone Calls To: (302) 658-9141	
FULL NAME OF SOLE OR FIRST INVENTOR Jerome Pierrard		INVENTOR'S SIGNATURE 	DATE Dec 22, 2000
RESIDENCE 3 Rue Hector Berlioz, 69009 Lyon, France		CITIZENSHIP France	
POST OFFICE ADDRESS 3 Rue Hector Berlioz, 69009 Lyon, France			
FULL NAME OF SECOND JOINT INVENTOR IF ANY Carole Guitton		INVENTOR'S SIGNATURE 	DATE 122/12/2000
RESIDENCE 23 Rue du Petit Montessuy, 69009 Lyon, France		CITIZENSHIP France	
POST OFFICE ADDRESS 23 Rue du Petit Montessuy, 69009 Lyon, France			
FULL NAME OF THIRD JOINT INVENTOR IF ANY Olivier Favre-Bulle		INVENTOR'S SIGNATURE 	DATE 22/12/2000
RESIDENCE 113 Rue Baraban, 69003 Lyon, France		CITIZENSHIP France	
POST OFFICE ADDRESS 113 Rue Baraban, 69003 Lyon, France			
FULL NAME OF FOURTH JOINT INVENTOR IF ANY		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FIFTH JOINT INVENTOR IF ANY		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR IF ANY		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			